Compulsory Licensing (CL) is one of the most important and widely debated mechanisms in patent law because it represents a carefully crafted balance between the exclusive rights granted to patent holders and the broader public interest in ensuring access to essential inventions, technologies, medicines, and innovations. The concept of compulsory licensing recognizes that while patents serve as incentives for research, development, and technological advancement by granting inventors temporary monopolies over their inventions, these monopolies should not be exercised in a manner that adversely affects public welfare, restricts access to critical products, or impedes economic and technological development.
In India, the legal framework governing compulsory licensing is contained primarily in Chapter XVI of the Patents Act, 1970, which establishes detailed provisions relating to the grounds, conditions, procedures, and limitations governing the grant of compulsory licences. The Indian compulsory licensing regime is internationally recognized as one of the most comprehensive and balanced systems in the world because it seeks to harmonize the interests of patent holders, industry participants, consumers, public health authorities, and society at large.
The concept is also fully consistent with India’s obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which permits member countries to adopt compulsory licensing measures under specified circumstances. Compulsory licensing may be broadly defined as a statutory authorization granted by a government authority permitting a third party to manufacture, use, sell, distribute, or otherwise exploit a patented invention without the consent of the patent holder, subject to payment of adequate remuneration.
Unlike voluntary licences, which arise through contractual arrangements between patent owners and licensees, compulsory licences are imposed by law when certain conditions are satisfied. The rationale behind compulsory licensing is rooted in the principle that patents are granted not merely to reward inventors but also to promote technological progress, industrial development, and public welfare. Consequently, when a patent holder fails to make the patented invention adequately available to the public, charges excessive prices, or otherwise acts in a manner inconsistent with the objectives of patent law, the State may intervene through compulsory licensing to address the imbalance.
The legal foundation of compulsory licensing in India is primarily found in Sections 84 to 92A of the Patents Act, 1970. Section 84 constitutes the central provision governing ordinary compulsory licensing and permits any interested person to apply for a compulsory licence after the expiration of three years from the date of grant of a patent. The applicant must establish the existence of one or more statutory grounds specified under the Act. The first ground is that the reasonable requirements of the public with respect to the patented invention have not been satisfied. This requirement reflects the fundamental objective that patented inventions should serve societal needs rather than remain inaccessible.
The expression “reasonable requirements of the public” encompasses various considerations, including availability of the invention, adequacy of supply, demand within the market, and the extent to which the invention contributes to public welfare. If a patented product or process is unavailable in sufficient quantities to meet public demand, a compulsory licence may be justified. The second ground for compulsory licensing is that the patented invention is not available to the public at a reasonably affordable price. Affordability is a particularly significant consideration in developing countries such as India, where access to essential products, especially medicines, can have profound implications for public health and social welfare.
Patent holders are entitled to recover their investments and earn reasonable profits, but the law seeks to prevent situations where excessively high prices effectively deny public access to important inventions. Determining whether a price is reasonably affordable requires consideration of various factors, including the economic circumstances of consumers, the nature of the invention, manufacturing costs, market conditions, and the broader public interest. The third ground for compulsory licensing under Section 84 is that the patented invention is not worked in the territory of India.
The concept of “working” a patent refers to the commercial exploitation of the invention in a manner that contributes to industrial development and technological advancement within the country. Although Indian law does not mandate local manufacturing in every case, it emphasizes that patents should not be used merely as instruments for import monopolies without contributing meaningfully to domestic industry. The issue of working received considerable judicial attention in Bayer Corporation v. Union of India and Natco Pharma Ltd., where the Bombay High Court examined whether Bayer’s anti-cancer drug Nexavar was being adequately worked in India.
The court observed that importation may, in certain circumstances, constitute working of a patent, but patent holders relying solely on imports must demonstrate that such arrangements satisfy the objectives of the Patents Act and adequately serve public needs. The Bayer-Natco dispute became historically significant because it resulted in India’s first compulsory licence for a pharmaceutical product. Natco Pharma applied for a compulsory licence to manufacture a generic version of Nexavar, arguing that Bayer had failed to satisfy public demand, had priced the drug beyond the reach of most patients, and had not sufficiently worked the patent in India.
The Controller of Patents granted the compulsory licence, and the decision was subsequently upheld by the Intellectual Property Appellate Board and the Bombay High Court. The case established important precedents concerning affordability, public requirements, and working of patents and remains one of the most influential decisions in Indian patent jurisprudence. In addition to ordinary compulsory licences under Section 84, the Patents Act contains several special provisions addressing extraordinary circumstances. Section 92 empowers the Central Government to notify compulsory licensing in situations involving national emergencies, circumstances of extreme urgency, or public non-commercial use.
Such circumstances may include epidemics, pandemics, natural disasters, public health crises, defence emergencies, or other situations requiring immediate access to patented technologies. Once a notification is issued, the Controller may grant compulsory licences without requiring applicants to wait for the expiration of three years from the grant of the patent. The significance of Section 92 became particularly evident during discussions concerning access to medicines and healthcare technologies during public health emergencies. The provision reflects the principle that public welfare considerations may, in exceptional situations, justify expedited access to patented inventions.
Section 92A introduces another important dimension to compulsory licensing by permitting compulsory licences for the manufacture and export of patented pharmaceutical products to countries with insufficient or no manufacturing capacity in the pharmaceutical sector. This provision was introduced to implement the Doha Declaration on the TRIPS Agreement and Public Health and reflects India’s commitment to facilitating access to essential medicines in developing countries. Under Section 92A, compulsory licences may be granted specifically for export purposes where the importing country has issued a compulsory licence or otherwise authorized importation of the pharmaceutical product.
This mechanism has significant implications for global public health because it enables countries lacking domestic manufacturing capabilities to obtain affordable medicines from Indian manufacturers. The grant of a compulsory licence is subject to several conditions designed to protect the legitimate interests of patent holders while advancing public welfare objectives. Section 90 of the Patents Act sets forth principles governing the terms and conditions of compulsory licences. One of the most important conditions is that the patent holder must receive reasonable remuneration taking into account the nature of the invention, the expenditure incurred in developing it, the extent of exploitation by the licensee, and other relevant circumstances.
This requirement ensures that compulsory licensing does not amount to expropriation of patent rights without compensation. The royalty rate awarded in the Bayer-Natco case, for example, was ultimately fixed at seven percent of net sales, reflecting an attempt to balance the interests of both parties. Another important condition is that compulsory licences should generally be non-exclusive and non-assignable. This means that the patent holder retains ownership of the patent and may continue exploiting the invention or granting licences to others. The compulsory licensee acquires only limited rights necessary to address the public interest concerns underlying the licence. Furthermore, the licence must predominantly serve the Indian market except in cases involving exports authorized under Section 92A.
The Controller also considers factors such as the ability of the applicant to work the invention effectively, the efforts made to obtain a voluntary licence on reasonable terms, the capacity of the applicant to satisfy public demand, and the public interest implications of granting the licence. The applicant is generally required to demonstrate that reasonable efforts were made to obtain authorization from the patent holder on commercial terms and that such efforts were unsuccessful within a reasonable period. However, this requirement may be waived in cases involving national emergencies, extreme urgency, or public non-commercial use. While compulsory licensing serves important public policy objectives, it is also subject to significant limitations designed to preserve incentives for innovation and investment.
Excessive or arbitrary use of compulsory licensing could undermine confidence in the patent system, discourage research and development, reduce foreign investment, and weaken incentives for technological innovation. Consequently, compulsory licences are regarded as exceptional measures rather than routine regulatory tools. The procedural safeguards contained in the Patents Act ensure that compulsory licences are granted only after careful examination of the relevant facts and circumstances. Patent holders are entitled to receive notice of applications, present evidence, challenge allegations, and seek judicial review of adverse decisions. These safeguards help maintain a balance between private rights and public interests. Internationally, compulsory licensing remains a subject of considerable debate.
Developed countries often emphasize the importance of strong patent protection in promoting innovation, while developing countries frequently highlight the need for flexibility in addressing public health and developmental challenges. The TRIPS Agreement recognizes both perspectives by permitting compulsory licensing while establishing conditions intended to protect patent holders. The Doha Declaration on TRIPS and Public Health further affirmed the right of member states to utilize compulsory licensing and other flexibilities to protect public health and promote access to medicines. India’s compulsory licensing framework is widely regarded as a model of how these competing objectives can be reconciled within a coherent legal system. The significance of compulsory licensing extends beyond pharmaceuticals.
Although public attention often focuses on medicines, compulsory licensing may also apply to agricultural technologies, renewable energy innovations, telecommunications technologies, industrial processes, biotechnology inventions, and other patented products or processes where public interest considerations arise. As technological innovation becomes increasingly important to economic development, compulsory licensing will continue to serve as an important mechanism for balancing innovation incentives with societal needs. In conclusion, compulsory licensing under the Patents Act, 1970 represents a vital legal instrument that seeks to reconcile the exclusive rights of patent holders with the broader objectives of public welfare, technological dissemination, economic development, and access to essential inventions.
Through provisions such as Sections 84, 90, 92, and 92A, the Act establishes a comprehensive framework governing the grounds, conditions, and limitations applicable to compulsory licences. The statutory grounds of unmet public requirements, lack of reasonable affordability, and failure to work the patent in India reflect the principle that patents must ultimately serve societal interests. At the same time, safeguards such as reasonable remuneration, procedural fairness, non-exclusivity, and judicial oversight ensure that the legitimate interests of innovators remain protected. The Indian compulsory licensing regime therefore exemplifies a balanced approach to intellectual property governance, promoting innovation while ensuring that patent rights do not become obstacles to public welfare, healthcare accessibility, technological progress, and sustainable economic growth.
Leave a Reply